Enliven Therapeutics, Inc. (ELVN) SEC Filings & Earnings Calls

Clinical-stage biotech with no revenue and history of losses

“The Company has incurred significant losses and negative cash flows from operations since inception.” · word for word

Geopolitical risk from clinical trial sites in Israel

“The Company has established clinical trial sites in Israel, which may face recruitment, enrollment, retention, operational or other difficulties due to conflicts within the region.” · word for word

Clinical-stage biotech with no approved products; net loss widening to $32.5M from $25.3M YoY.

“Net loss of $32.5 million for the second quarter of 2026, compared to a net loss of $25.3 million for the second quarter of 2025” · word for word

Phase 3 trial execution risk; ENABLE-2 trial design not fully finalized, with End-of-Phase 2 meeting expected in Q3 2026.

“Additional details of the Phase 3 trial design are expected to be finalized following further discussions with the FDA, including at a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026.” · word for word

Insider selling / activist stake reduction

“This Amendment No. 5 is being filed to report that as a result of the transactions described in Item 5 below, the beneficial ownership of the outstanding Shares that the Reporting Persons may be deemed to beneficially own decreased by more than 1%.” · word for word

Insider selling / activist stake reduction

“This Amendment No. 5 is being filed to report that as a result of the transactions described in Item 5 below, the beneficial ownership of the outstanding Shares that the Reporting Persons may be deemed to beneficially own decreased by more than 1%.” · word for word

Dilution risk from offering and potential additional 1.6M shares if underwriters exercise option.

“the Company has granted the Underwriters an option... to purchase up to an additional 1,600,000 shares”

Phase 1 data may not predict Phase 3 success; regulatory and clinical risks remain.

“Forward-looking statements... include... the potential for interim, topline and preliminary results... to materially change”

Clinical-stage biotech with no approved products; pipeline risk.

“Phase 1 data update for ELVN-001 expected mid-2026... Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026” · word for word

Clinical Development Risk

“The Company is subject to risks common to development-stage companies in the biotechnology industry including, but not limited to, risks of failure of preclinical studies and clinical trials.” · word for word

Financing Risk

“Until the Company can generate a sufficient amount of revenue from the commercialization of its product candidates, the Company will require substantial additional capital.” · word for word

Geopolitical Risk

“The Company has established clinical trial sites in Israel, which may face recruitment, enrollment, retention, operational or other difficulties due to conflicts within the region.” · word for word

Regulatory Risk

“The Company is subject to risks of obtaining regulatory approval for any product candidate that it may develop.”

Dilution from authorized share increase

“any future issuance of additional authorized shares of our common stock may, among other things, dilute the earnings per share of common stock and the equity and voting rights of those holding common stock at the time the additional shares are issued.” · word for word

Anti-takeover effect from authorized shares

“our ability to issue additional shares of common stock could, under certain circumstances, have an anti-takeover effect” · word for word

Single product dependency

“We are substantially dependent on ELVN-001. If we are unable to advance ELVN-001 through clinical development, obtain regulatory approval and ultimately commercialize or license ELVN-001, or experience significant delays in doing so, our business will be materially harmed.” · word for word

No revenue and high cash burn

“We have incurred significant net losses and we expect to continue to incur significant net losses for the foreseeable future.” · word for word

Clinical trial failure risk

“The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.” · word for word

Clinical-stage company with no approved products or revenue; dependent on successful clinical trials and regulatory approvals.

“clinical-stage biopharmaceutical company; net loss of $103.7 million for full year 2025”

Execution risk on Phase 3 trial and commercialization; reliance on key personnel transition.

“CEO change at critical juncture; pivotal Phase 3 trial for ELVN-001 planned for 2026.”

Clinical-stage biotech development risk

“The Company is subject to risks common to development-stage companies in the biotechnology industry including, but not limited to, risks of failure of preclinical studies and clinical trials.” · word for word

Geopolitical risk from clinical trial sites in Israel

“The Company has established clinical trial sites in Israel, which may face enrollment, retention, operational or other difficulties due to conflicts within the region.” · word for word

Clinical-stage company with no approved products; high dependency on trial success.

“Net loss of $20.1 million; no revenue from product sales.”